Moxonidin Stada (Moxonidine)

Moxonidine works by selectively activating imidazoline I1 receptors in the brainstem. This activation dampens sympathetic outflow, leading to reduced peripheral vascular resistance and a modest decline in cardiac output, which together lower arterial blood pressure.

The dosage of Moxonidin Stada is determined by the prescribing clinician based on the individual’s blood‑pressure profile, age, renal function and response to therapy. The prescriber will select an appropriate starting dose and may adjust it according to clinical guidelines and patient tolerance.

Safety data for moxonidine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Moxonidine belongs to the imidazoline receptor agonist class, which differs from beta‑blockers, ACE inhibitors or calcium‑channel blockers. Compared with clonidine, another central antihypertensive, moxonidine generally produces fewer sedative and dry‑mouth side effects while offering comparable blood‑pressure reduction.

Moxonidin Stada tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep the product out of reach of children.

The medication is taken orally as a whole tablet, swallowed with a glass of water. It can be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing and any specific dietary considerations.

The most serious adverse events include severe hypotension, which can cause fainting, bradycardia (abnormally slow heart rate), and allergic reactions that may present as rash, swelling or difficulty breathing. Patients should seek immediate medical attention if any of these symptoms occur.

Moxonidin Stada is contraindicated in patients with known hypersensitivity to moxonidine or any excipients, those with severe hypotension, and individuals with certain cardiac conduction disorders such as advanced heart block. Clinicians should also exercise caution in patients with significant renal impairment.